Drug shows promise for stopping excessive sweating
NCT ID NCT01855256
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested the drug oxybutynin in 62 adults with excessive sweating (hyperhidrosis). Participants took either oxybutynin or a placebo, starting at a low dose and increasing gradually. The study measured how well the drug reduced sweating and improved quality of life, while also tracking side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Oxybutynin
- What this could lead to
- If it works, this could provide a non-surgical treatment option for people with excessive sweating.
- What could go wrong
- This is a small, completed Phase 3 trial. While results are promising, the drug may cause side effects and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERHIDROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHG Landerneau
Landerneau, 29800, France
-
CHG de Morlaix
Morlaix, France, 29600, France
-
Dermatologist'S Office
Quimper, 29000, France
-
Hospital, Brest
Brest, 29609, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.